Cargando…

Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance

BACKGROUND: No approved targeted agents are available for esophageal squamous cell carcinoma (ESCC). Informative genomic analysis and mouse patient-derived xenografts (PDX) also called mouse avatar can greatly expedite drug discovery. METHODS: Six ESCC cell lines and 7 out of 25 PDX models derived f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhentao, Chen, Zuhua, Wang, Jingyuan, Zhang, Mengqi, Li, Zhongwu, Wang, Shubin, Dong, Bin, Zhang, Cheng, Gao, Jing, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114252/ https://www.ncbi.nlm.nih.gov/pubmed/30157900 http://dx.doi.org/10.1186/s13045-018-0651-z

Ejemplares similares

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2021)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
por: Cheong, Hio Teng, et al.
Publicado: (2018)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
por: van der Wekken, A. J., et al.
Publicado: (2017)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
por: Zhang, Hongye, et al.
Publicado: (2020)

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients
por: Chen, Zuhua, et al.
Publicado: (2020)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
por: Chen, Zuhua, et al.
Publicado: (2022)

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
por: Wang, Jiayuan, et al.
Publicado: (2017)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
por: Barrios-Bernal, Pedro, et al.
Publicado: (2022)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
por: Zhang, Guoqing, et al.
Publicado: (2022)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
por: Passaro, Antonio, et al.
Publicado: (2021)

Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization
por: Zou, Jianling, et al.
Publicado: (2018)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
por: Oya, Yuko, et al.
Publicado: (2021)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
por: Zhang, Shirong, et al.
Publicado: (2015)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
por: Yu, Tao, et al.
Publicado: (2020)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
por: Falk, Markus, et al.
Publicado: (2023)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
por: Tu, Hai-Yan, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
por: Kim, Minhye, et al.
Publicado: (2021)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
por: Chen, Shubin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ij4nff3tk9o4h8cpec0papenkq